Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials
2024

Delgocitinib Ointment Dosing in Children

Sample size: 240 publication 10 minutes Evidence: moderate

Author Information

Author(s): Fukuie Tatsuki, Toyama Hiroyuki, Tanaka Mai, Ohashi‐Doi Katsuyo, Kabashima Kenji

Primary Institution: National Center for Child Health and Development, TORII Pharmaceutical Co Ltd, Graduate School of Medicine Kyoto University

Hypothesis

What is the efficacy and safety of delgocitinib ointment in different concentrations for treating pediatric atopic dermatitis?

Conclusion

Delgocitinib 0.5% ointment may be more effective than the 0.25% dose for mild atopic dermatitis, and it is well tolerated when used in combination with topical corticosteroids and/or tacrolimus ointment.

Supporting Evidence

  • 46.2% of subjects with mild disease achieved clear or almost clear skin with 0.25% delgocitinib.
  • 71.4% of subjects with mild disease achieved clear or almost clear skin with 0.5% delgocitinib.
  • 19.0% of subjects with moderate to severe disease achieved clear or almost clear skin with 0.25% delgocitinib.
  • 20.0% of subjects with moderate to severe disease achieved clear or almost clear skin with 0.5% delgocitinib.
  • No overall differences in safety profiles between the two doses were observed.

Takeaway

This study looked at a cream called delgocitinib for kids with skin problems. They found that a stronger version of the cream works better for mild cases and is safe to use with other medicines.

Methodology

Post-hoc analysis of data from two double-blind placebo-controlled trials comparing the efficacy and safety of 0.25% and 0.5% delgocitinib ointment in pediatric patients with atopic dermatitis.

Potential Biases

No data on the correlation between treatment-related adverse events and delgocitinib dose were collected.

Limitations

The study is based on post-hoc analyses of short-term treatment data from a relatively small number of patients.

Participant Demographics

Pediatric patients aged 2-15 years with atopic dermatitis.

Digital Object Identifier (DOI)

10.1111/ped.15798

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication